NCT00539838View on ClinicalTrials.gov

A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)

PHASE3TerminatedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

December 19, 2007

Primary Completion Date

July 12, 2011

Study Completion Date

July 12, 2011

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

Prednisone

Oral repeating dose

DRUG

Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate)

Oral repeating dose

DRUG

Methylprednisolone

Intravenous repeating dose

DRUG

Ocrelizumab

Intravenous repeating dose

DRUG

Placebo

Intravenous repeating dose

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

lead

Genentech, Inc.

INDUSTRY

NCT00539838 - A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN) | Biotech Hunter | Biotech Hunter